Pharmacology of hormonal contraceptives and acne

Cutis

Volumn 81, Issue 1 SUPPL., 2008, Pages 8-12

  O'Connell, Katharine ^a   Westhoff, Carolyn ^b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANE DERIVATIVE; BIOLOGICAL MARKER; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN;

ACNE VULGARIS; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; REVIEW; SEBUM;

ACNE VULGARIS; ANDROGENS; ANDROSTANES; BIOLOGICAL MARKERS; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; SEBUM; SEX HORMONE-BINDING GLOBULIN;

EID: 39049124712     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Thiboutot D, Knaggs H, Gilliland K, et al. Activity of 5-alpha-reductase and 17-beta-hydroxysteroid dehydrogenase in the infrainfundibulum of subjects with and without acne vulgaris. Dermatology. 1998;196:38-42.
2. Azziz R, Gay F. The treatment of hyperandrogenism with oral contraceptives. Semin Reprod Endocrinol. 1989;7: 246-254.
3. Imperato-McGinley J, Gautier T, Cai LQ, et al. The androgen control of sebum production, studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab. 1993;76:524-528.
4. Murphy A, Cropp CS, Smith BS, et al. Effect of low-dose oral contraceptive on gonadotropins, androgens, and sex hormone binding globulin in nonhirsute women. Fertil Steril. 1990;53:35-39.
5. Pye RJ, Meyrick G, Pye MJ, et al. Effect of oral contraceptives on sebum excretion rate. BMJ. 1977;2: 1581-1582.
6. Fotherby K, Caldwell AD. New progestogens in oral contraception. Contraception. 1994;49:1-32.
7. Thorneycroft IH, Stanczyk FZ, Bradshaw KD, et al. Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception. 1999;60:255-262.
8. Cassidenti DL, Paulson RJ, Serafini P, et al. Effects of sex steroids on skin 5 alpha-reductase activity in vitro. Obstet Gynceol. 1991;78:103-107.
9. Dean HJ, Winter JSD. The effect of five synthetic progestational compounds on 5α-reductase activity in genital skin fibroblast monolayers. Steroids. 1984;43: 13-23.
10. Lemay A, Langley RG. The use of low dose oral contraceptives for the management of acne. Skin Ther Lett. 2002;7:1-5.
11. Palatsi R, Reinila M, Kivinén S. Pituitary function and DHEA-S in male acne and DHEA-S prolactin and cortisol before and after oral contraceptive treatment in female acne. Acta Derm Venereol. 1986;66:225-230.
12. Rosen MP, Breitkopf DM, Nagamani M. A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris. Am J Obstet Gynecol. 2003;188:1158-1160.
13. Leyden J, Shalita A, Hordinsky M, et al. Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: a randomized, placebo-controlled trial. J Am Acad Dermatol. 2002;47:399-409.
14. van Vloten WA, van Haselen CW, van Zuuren EJ, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002;69(suppl 4):2-15.
15. Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis. 2004;74:123-130.
16. Thiboutot D, Archer DF, Lemay A, et al. A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. Fertil Steril. 2001;76: 461-468.